Suppr超能文献

住院环境中启动血管紧张素受体/中性肽链内切酶抑制剂之前的血管紧张素转换酶抑制剂洗脱期。

Angiotensin-Converting Enzyme Inhibitor Washout Period Prior to Angiotensin Receptor/Neprilysin Inhibitor Initiation in the Inpatient Setting.

作者信息

Shah Kaanan, Mabhugu Stella, Obioma Jessica, Nguyen Quang, Schillig Jessica, Torres Brittany P, Howard Meredith, Lindley Bryn

机构信息

College of Pharmacy, The University of North Texas Health Science Center, Fort Worth, TX, USA.

Henry Ford Hospital, Henry Ford Health, Detroit, MI, USA.

出版信息

Ann Pharmacother. 2025 Sep;59(9):835-838. doi: 10.1177/10600280241282324. Epub 2024 Nov 4.

Abstract

BACKGROUND

The 2022 AHA-ACC HFSA Guideline for Management of Heart Failure recommend initiating an angiotensin receptor/neprilysin inhibitor (ARNI) in patients with heart failure with reduced ejection fraction (HFrEF) who can tolerate an angiotensin-converting enzyme inhibitor (ACEi). The manufacturer recommends initiating a 36-hour washout period when switching from ACEi to ARNI due to an increased risk of adverse effects, including angioedema. This study investigated the adherence to the washout period when transitioning from ACEi to ARNI at a community hospital.

OBJECTIVES

The primary objective was to assess the rate of adherence to the 36-hour washout when transitioning patients from ACEi to ARNI. Secondary outcomes included heart failure exacerbation readmission rates within 90 days and the rate of adverse effects (angioedema, hypotension, acute kidney injury, and hyperkalemia).

METHODS

This was a retrospective cohort study including patients with HFrEF who were transitioned from ACEi to ARNI during their hospital stay between March 1, 2016 and December 31, 2022. Patients were excluded if they did not receive an ACEi or ARNI during their admission or if they had an ejection fraction >40%. Pearson chi-square was used to analyze categorical data.

RESULTS

Of 33 patients included in this study, 67% received the full 36-hour washout period when transitioning from ACEi to ARNI. There were no significant differences between the rates of hospital readmissions or adverse effects between the groups. No patients experienced hyperkalemia or angioedema.

CONCLUSION AND RELEVANCE

This is the first study to our knowledge to describe real-world prescribing practices when transitioning patients from ACEi to ARNI for the treatment of HFrEF. Larger, multicenter studies are needed to provide more data on prescribing practices outside this single center. Future research should also include pharmacist's role in adhering to the recommended washout.

摘要

背景

2022年美国心脏协会(AHA)-美国心脏病学会(ACC)-心力衰竭学会(HFSA)心力衰竭管理指南建议,对于射血分数降低的心力衰竭(HFrEF)患者,若能耐受血管紧张素转换酶抑制剂(ACEi),则起始使用血管紧张素受体/脑啡肽酶抑制剂(ARNI)。由于不良反应风险增加,包括血管性水肿,制造商建议从ACEi转换为ARNI时开始36小时的洗脱期。本研究调查了在社区医院从ACEi转换为ARNI时对洗脱期的依从性。

目的

主要目的是评估患者从ACEi转换为ARNI时对36小时洗脱期的依从率。次要结局包括90天内心力衰竭加重再入院率和不良反应发生率(血管性水肿、低血压、急性肾损伤和高钾血症)。

方法

这是一项回顾性队列研究,纳入了2016年3月1日至2022年12月31日住院期间从ACEi转换为ARNI的HFrEF患者。如果患者在入院期间未接受ACEi或ARNI,或射血分数>40%,则排除在外。采用Pearson卡方检验分析分类数据。

结果

本研究纳入的33例患者中,67%在从ACEi转换为ARNI时接受了完整的36小时洗脱期。两组之间的再入院率或不良反应发生率无显著差异。没有患者发生高钾血症或血管性水肿。

结论及意义

据我们所知,这是第一项描述将患者从ACEi转换为ARNI治疗HFrEF时的实际处方做法的研究。需要开展更大规模的多中心研究,以提供关于该单一中心以外处方做法的更多数据。未来的研究还应包括药师在遵守推荐洗脱期方面的作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验